medigraphic.com
ISSN 1561-3011 (Electronic)

2013, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2013; 32 (2)

CD4+ T-lymphocytes and viral load in elderly patients with HIV/AIDS who receive antiretroviral treatment

Hernández RD, Abad LY, Valle CEB

Language: Spanish
References: 21
Page: 139-146
PDF size: 68.35 Kb.


ABSTRACT

Background: Infection with the Human Immunodeficiency Virus (HIV) is a major health problem. The functional capacity of the immune system gradually declines with aging.
Objective: To demonstrate that the elderly patients with HIV/AIDS who follow treatment with antiretroviral drugs present a fall in viral load and a rise in the CD4+ T-lymphocytes with this treatment.
Methods: A cross-sectional prospective observational study was conducted in 44 HIV/AIDS patients attended in the Medical Services offered by IPK who received treatment with different antiretroviral schemes.
Results: It was observed that there was an average rise of 97 cel/µL in the CD4+ T-lymphocytes, as well as an average fall of 3 583 cp/µL in viral load after the antiretroviral treatment.
Conclusions: With this study, we can conclude that there was a rise in CD4+ T-lymphocytes and a fall in the viral load in the elderly patients with HIV/AIDS who followed treatment with antiretroviral drugs, what evidences the immunological reconstitution and virologic control of these patients with the use of antiretroviral therapy.


REFERENCES

  1. Curran JW, Jafe HW, Ardí AM, Morgan WM, Selik RM, Dondero TJ. Epidemiology of HIV infection and AIDS in the United Status. Science. 2008;239:610-6.

  2. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4:240-6.

  3. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol. 2008;152:201-10.

  4. Mayer K, Pizer HF, Venkatesh KK. The social ecology of HIV/AIDS. Med Clin North Am. 2008;92:1363-75.

  5. Wayne SJ, Rhyne RL, Garry PJ, Goodwin JC. Cell mediated immunity as predictor of morbidity and mortality in subjects over 60 years. J. Gerontol Med Sci. 2009;45:145-8.

  6. Wilmoth JR. Demografhy of longevity: past, present, and future trends. Exp Gerontol. 2000;35:1111-29.

  7. Bestilny LJ, Gill MJ, Mody CH, Riabowol KT. Accelerated replicative senescence of the peripheral immune system induced by HIV infection. AIDS. 2010;14:771-80.

  8. Effros RB. Telomeres and HIV disease. Microbes Infect. 2009;2:69-76.

  9. Anuario Estadístico de Salud en Cuba. [Revisado mayo 2011]. Disponible en: http://www.infomed.sld.cu/servicios/estadistica.

  10. Cansio I, Sánchez J, Reymond V, López VJ. Información Básica sobre la atención integral a personas viviendo con VIH/sida. La Habana: Editorial Lazo Adentro, 2006.

  11. Redi R, Calza L. HIV infection and AIDS in advanced age. Epidemiological and clinical issues, therapeutic and management problems. Infez Med. 2004;12(3):152-73.

  12. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-91.

  13. Bhavan KP. The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008;5(3):150-8.

  14. Machado Hernández M, Casas León PM, Luna González D. Atención secundaria de pacientes con VIH/SIDA en el Hospital General "Camilo Cienfuegos". Sancti Spíritus. Gaceta Médica Espirituana. 2008;2010 [Acceso: 8 de mayo de 2012];12(3). Disponible en: http://bvs.sld.cu/revistas/gme/pub/vol.12.%283%29_02/p2.html

  15. World Health Organization. Antiretroviral therapy. [Revisado en abril, 2010]. Disponible en: http://www.who.int/hiv/topics/treatment/en/index.html

  16. Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Millar S. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Rev The Lancet. 2004;363(4):1253-63.

  17. Gwenda V, Mike S, Hermione L, Vas N, Diane MG, Gillian D, et. al. Nevirapine use in HIV infected children. AIDS. 2003;17(11):1639-47.

  18. Pérez J, Ortega LM. Pautas para el manejo de la infección por VIH/sida. La Habana, Cuba: 2007.

  19. MacArthur RD. Comparison of prognostic significance of latest CD4 cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005;6:127-35.

  20. Monforte A, Lepri A, Rezza G. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naďve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naďve Patients. AIDS. 2000;14:499-507.

  21. Dorrucci M, Pezzotti P, Grisorio B. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor and nonnucleoside reverse transcriptase inhibitor containing regimen. AIDS. 2001;15:1733-6.




2020     |     www.medigraphic.com